Drug Profile
ADXS DUAL - Ayala Pharmaceuticals
Alternative Names: ADXS-602; ADXS-DUAL; Second generation axalimogene filolisbacLatest Information Update: 23 Jan 2023
Price :
$50
*
At a glance
- Originator Advaxis
- Developer Ayala Pharmaceuticals
- Class Antineoplastics; Cancer vaccines; Gene therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer
Most Recent Events
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 22 Oct 2020 No development reported - Phase-III for Cervical cancer (Combination therapy, Metastatic disease) in USA (Parenteral)
- 16 Mar 2018 An investigator-sponsored phase II trial is planned for Head and neck cancer (Metastatic disease) in 2018